natgillin/translations-raw huggingface dataset:
an enteric coating which provides for release of the bisphosphonate and the EDTA in the lower gastrointestinal tract of a mammal; 
enteričkog sloja koji služi za oslobađanje bisfosfonata i EDTA u nižem gastrointestinalnom traktu sisavaca;
wherein the molar ratio of the disodium EDTA to the bisphosphonate is at least 2:1. 
naznačen time da je molarni omjer dinatrijeve EDTA u bisfosfonatu najmanje 2:1.
The oral dosage form according to Claim 1 or Claim 2 wherein the oral dosage form provides for release of the bisphosphonate and the EDTA as a bolus in the lower gastrointestinal tract, preferably in the large intestine. 
Oralni oblik za doziranje prema zahtjevu 1 ili zahtjevu 2, naznačen time da oralni oblik za doziranje omogućuje oslobađanje bisfosfonata i EDTA kao bolus u nižem gastrointestinalnom traktu, poželjno u debelom crijevu.
An oral sustained release pharmaceutical composition comprising melt granules of imatinib or any of its salts and a release retardant, and which comprises at least 400 mg of imatinib mesylate. 
Oralni farmaceutski sastav s odgođenim otpuštanjem, naznačen time, da sadrži rastaljene granule imatiniba ili bilo koju od njegovih soli i usporivač otpuštanja, te koji sadrži najmanje 400 mg imatinib mesilata.
The pharmaceutical composition of Claim 2, wherein said composition comprises between 62% and 99 % by weight of imatinib. 
Farmaceutski sastav prema Zahtjevu 1, naznačen time, da spomenuti sastav sadrži između 62 i 99 masenih % imatiniba.
The pharmaceutical composition of Claim 1, wherein said release retardant is a polymer. 
Farmaceutski sastav prema Zahtjevu 1, naznačen time, da spomenuti usporivač otpuštanja je polimer.
The pharmaceutical composition of Claim 4, wherein said polymer has a glass transition temperature less than the melting point of imatinib mesylate. 
Farmaceutski sastav prema Zahtjevu 4, naznačen time, da spomenuti polimer ima temperaturu prijelaznog vremena prozirnosti nižu od tališta imatinib mesilata.
The pharmaceutical composition of Claim 5, further comprising a plasticizer. 
Farmaceutski sastav prema Zahtjevu 5, naznačen time, da nadalje sadrži plastifikator.
The pharmaceutical composition of Claim 1, wherein said release retardant is a non-polymeric release retardant. 
Farmaceutski sastav prema Zahtjevu 1, naznačen time, da spomenuti usporivač otpuštanja je ne-polimerni usporivač otpuštanja.
The pharmaceutical composition of Claim 7, wherein said non-polymeric release retardant melts at a temperature less than the melting point of imatinib or the imatinib salt employed. 
Farmaceutski sastav prema Zahtjevu 7, naznačen time, da se spomenuti ne-polimerni usporivač otpuštanja rastaljuje na temperaturi nižoj nego što je talište imatiniba ili soli imatiniba koje su u upotrebi.
The pharmaceutical composition of Claim 7, wherein said non-polymeric release retardant is hydrogenated castor oil. 
Farmaceutski sastav prema Zahtjevu 7, naznačen time, da spomenuti ne-polimerni usporivač otpuštanja je hidrogenirano ricinovo ulje.
The pharmaceutical composition of Claim 1, wherein the pharmaceutical composition comprises at least one release retardant selected from the group consisting of water soluble, water insoluble and water swellable cellulose polymers, acrylic polymers, polysaccharides and polyols. 
Farmaceutski sastav prema Zahtjevu 1, naznačen time, da farmaceutski sastav sadrži barem jedan usporivač otpuštanja odabran iz skupine koja se sastoji od celuloznih polimera, akrilnih polimera, polisaharida i poliola, koji su topivi u vodi, koji nisu topivi u vodi i koji nabubre u vodi.
The pharmaceutical composition of Claim 1, wherein the pharmaceutical composition comprises at least one release retardant selected from the group consisting of hydroxypropyl cellulose, hydroxypropylmethyl cellulose, ethylcellulose and methacrylate polymers. 
Farmaceutski sastav prema Zahtjevu 1, naznačen time, da farmaceutski sastav sadrži barem jedan usporivač otpuštanja odabran iz skupine koja se sastoji od hidroksipropilne celuloze, hidroksipropilmetilne celuloze, etilceluloze i metakrilatnih polimera.
A method of making an oral sustained release pharmaceutical composition comprising the step of melt granulating imatinib or any of its salts with a release retardant and optionally a release modifier in an extruder while heating to a temperature below the melting temperature of imatinib or its salt, to form melt granules, and wherein the composition comprises at least 50% imatinib by weight of the composition. 
Postupak izrade oralnog farmaceutskog sastava s odgođenim otpuštanjem, naznačen time, da sadrži korak rastaljivanja granuliranog imatiniba ili bilo koje njegove soli s usporivačem otpuštanja i opcijski s modifikatorom otpuštanja u ekstruderu gdje se vrši zagrijavanje na temperaturu ispod temperature taljenja imatiniba ili njegovih soli, kako bi se oblikovale rastaljene granule, pri čemu sastav sadrži najmanje 50 % imatiniba po masi sastava.
The method of claim 13, wherein the melt granules are once again Introduced into the extruder, to further granulate with or without release retardant or release modifier or plasticizer, at a temperature less than the melting point of imatinib or the imatinib salt employed. 
Postupak prema Zahtjevu 13, naznačen time, da se rastaljene granule stavljaju još jednom u ekstruder, na daljnje granuliranje sa ili bez usporivača otpuštanja ili modifikatora otpuštanja ili plastifikatora, na temperaturi nižoj od tališta imatiniba ili soli imatiniba koje su u upotrebi.
The method of claim 13, further comprising cooling of said melt granules to a desired temperature, which is less than melt granulation process temperature. 
Postupak prema Zahtjevu 13, naznačen time, da nadalje obuhvaća hlađenje spomenutih rastaljenih granula na željenu temperaturu, koja je niža od temperature u postupku taljenja i granuliranja.
The pharmaceutical composition according to any one of claims 1 to 12, wherein the composition provides, in healthy humans, a mean plasma concentration value not exceeding 3.5µg Imatinib/mL, when dosed 2 hours after a light breakfast. 
Farmaceutski sastav prema bilo kojem od Zahtjeva 1 do 12, naznačen time, da sastav opskrbljava, kod zdravih ljudi, prosječnu vrijednost koncentracije u plazmi koja ne prelazi 3,5μg Imatinib/mL, kada se dozira 2 sata nakon laganog doručka.
The method of claim 6, wherein heat is supplied to initiate and/or maintain the reaction. 
Postupak prema zahtjevu 6, naznačen time, da se zagrijavanje dostavlja kako bi se potakla i/ili održavala reakcija.
The method of claim 6, wherein cooling is supplied to slow down the reaction. 
Postupak prema zahtjevu 6, naznačen time, da se hlađenje dostavlja kako bi se usporavala reakcija.
The method of any of claims 1 to 11, wherein the 1st reactant is a compound of formula R4(CO)R5 VI, wherein R4 is selected from the group consisting of hydrogen, C1-6-alkyl, alkenyl, alkynyl, C3-10-cycloalkyl, aryl, heteroaryl, aralkyl and dialkylamino, and wherein R5 is selected from the group consisting of C1-6-alkyl, alkenyl, alkynyl, C3-10-cycloalkyl, aryl, heteroaryl, aralkyl, dialkylamino, di-C3-10-cycloalkylamino, diarylamino and diheteroarylamino. 
Postupak prema bilo kojem zahtjevu od 1 do 11, naznačen time, da je prvi reaktant spoj formule (CO)R5 VI, gdje R4 je odabaran iz skupine koja se sastoji od vodika, C1-6-alkila, alkenila, alkinila, C3-10-cikloalkila, arila, heteroarila, aralkila i dialkilamina, dok je R5 odabran iz skupine koja se sastoji od C1-6-alkila, alkenila, alkinila, C3-10-cikloalkila, arila, heteroarila, aralkila, dialkilamina, di-C3-10-cikloalkilamina, diarilamina i diheteroarilamina.
A peptide characterized by its capacity of binding to Transforming Growth Factor β1 (TGF-β1), wherein the amino acid sequence of said peptide is SEQ ID NO: 17, or a fragment of said peptide with capacity of binding to TGF-β1 comprising between 9 and 14 consecutive amino acids, and their pharmaceutically acceptable salts. 
Peptid, naznačen time što se može vezati na transformirajući čimbenik rasta β1 (TGF-β1), gdje aminokiselinski slijed navedenog peptida je SEQ ID NO: 17, ili fragment navedenog peptida koji se može vezati na TGF-β1, kojeg čini između 9 i 14 uzastopnih aminokiselina, i njihove farmaceutski prihvatljive soli.
A DNA construct comprising a sequence of DNA according to claim 9. 
DNA konstrukt, naznačen time štosadrži slijed DNA u skladu s patentnim zahtjevom 9.
A process for the manufacture of a compound of the Formula IIa: wherein R is a suitable sulphonate ester; 
Postupak za dobivanje spoja formule IIa: [image] naznačen time da R je pogodan sulfonatni ester;
from a (C1-C6)alkyl-4-piperidinecarboxylate compound of the Formula III: which process comprises the steps of: 
iz (C1-C6)alkil-4-piperidinkarboksilatnog spoja prema formuli III: [image] koji postupak sadrži slijedeće korake:
reacting the (C1-C6)alkyl-4-piperidinecarboxylate compound of the Formula III with di- tert -butyl dicarbonate in the presence of toluene or xylene to form a first mixture comprising toluene or xylene, tert -butanol and a compound of the Formula IV: 
reakciju (C1-C6)alkil-4-piperidinkarboksilatnog spoja prema formuli III sa di-terc-butil dikarbonatom u prisutnosti toluena ili ksilena koji tvore prvu mješavinu koja sadrži toluen ili ksilen, terc-butanol i spoj prema formuli IV: [image]
reacting the compound of the Formula V with a suitable sulphonylating agent in situ to form a sulphonate ester in the presence of a suitable base and toluene to form the compound of the Formula IIa. 
reakcije spoja prema formuli V sa pogodnim sredstvom za sulfoniranje in situ koji tvore sulfonatni ester u prisutnosti pogodne baze i toluena koji tvore spoj prema formuli IIa.
A process according to claim 1, wherein the compound of Formula IIa is a compound of Formula II and the sulphonating agent is tosyl chloride. 
Postupak prema zahtjevu 1, naznačen time da spoj formule IIa je spoj formule II i sredstvo za sulfoniranje je tosil klorid [image]
A process according to claim 21, wherein the step (f) comprises crystallisation using a toluene and isohexane solvent system. 
Postupak prema zahtjevu 7, naznačen time da korak (f) sadrži kristalizaciju uz korištenje sustava otapala toluena i izoheksana.
is selected from the group consisting of hydrogen, methyl, and CF3; 
se R0 odabire iz skupine koju sačinjavaju vodik, metil, i CF3;
is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, trifluoromethyl, 2,2,2-trifluoroethyl, methoxy, methoxy and methyl-carbonyl; 
se R1 odabire iz skupine koju sačinjavaju vodik, hidroksi, metil, etil, trifluorometil, 2,2,2-trifluoroetil, metoksi, metoksi i metil-karbonil;
wherein the aryl, cycloalkyl, partially unsaturated carbocyclyl, heteroaryl or heterocycloalkyl group, whether alone or as part of a substituent group, is optionally substituted with one or more substituents independently selected from the group consisting of C1-4alkyl, C1-4alkoxy, halogen substituted C1-4alkyl, halogen substituted C1-4alkoxy, hydroxy substituted C1-4alkyl, hydroxy, carboxy, cyano, nitro, amino, C1-4alkylamino, di(C1-4alkyl)amino, 5-tetrazolyl and 1-(1,4-dihydro-tetrazol-5-one); 
pri čemu je aril, cikloalkil, djelomično nezasićeni karbociklil, heteroaril ili heterocikloalkil, bilo samostalan ili kao dio supstituentske skupine, opcionalno supstituiran sa jednim ili više supstituenta koji se neovisno odabiru iz skupine koju sačinjavaju C1-4alkil, C1-4alkoksi, halogenom supstituiran C1-4alkil, halogenom supstituiran C1-4alkoksi, hidroksi skupinom supstituiran C1-4alkil, hidroksi, karboksi, cijano, nitro, amino, C1-4alkilamino, di(C1-4alkil)amino, 5-tetrazolil i 1-(1,4-dihidro-tetrazol-5-on);
wherein the cycloalkyl, aryl, heteroaryl, heterocycloalkyl or spiroheterocyclyl, whether alone or as part of a substituent group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, oxo, carboxy, C1-4alkyl, C1-4alkoxy, C1-4alkoxy-carbonyl, nitro, cyano, amino, C1-4alkylamino, di(C1-4alkyl)amino,-SO2-N(RCRD), 5-tetrazolyl and 1-(1,4-dihydro-tetrazol-5-one) 
pri čemu je cikloalkil, aril, heteroaril, heterocikloalkil ili spiro-heterociklil, bilo da je samostalan ili dio supstituentske skupine, opcionalno supstituiran sa jednim ili više supstituenata koji se neovisno odabiru iz skupine koju sačinjavaju halogen, hidroksi, okso, karboksi, C1-4alkil, C1-4alkoksi, C1-4alkoksi-karbonil, nitro, cijano, amino, C1-4alkilamino, di(C1-4alkil)amino, -SO2-N(RCRD), 5-tetrazolil i 1-(1,4-dihidro-tetrazol-5-on);
wherein each RV and RW is independently selected from the group consisting of hydrogen and C1-4alkyl; alternatively RV and RW are taken together with the N atom to which they are bound to form a 5 to 6 membered saturated, partially unsaturated or aromatic ring structure; 
pri čemu se svaki RV i RW neovisno odabiru iz skupine koju sačinjavaju vodik i C1-4alkil; alternativno RV i RW, zajedno sa dušikovim atomom na kojeg su vezani, tvore 5-ero do 6-eročlani zasićeni, djelomično nezasićeni ili aromatični prsten;
wherein the aryl, cycloalkyl, partially unsaturated carbocyclyl, heteroaryl or heterocycloalkyl group, whether alone or as part of a substituent group, is optionally substituted with one to two substituents independently selected from the group consisting of C1-4alkyl, C1-4alkoxy, halogen substituted C1-4alkyl, halogen substituted C1-4alkoxy, hydroxy substituted C1-4alkyl, hydroxy, carboxy, cyano, nitro, amino, C1-4alkylamino and di(C1-4alkyl)amino; 
pri čemu je arilna, cikloalkilna, djelomično nezasićena karbociklilna, heteroarilna ili heterocikloalkilna skupina, bilo sama ili kao dio supstituentske skupine, opcionalno supstituirana sa jednim do dva supstituenta koji se neovisno odabiru iz skupine koju sačinjavaju C1-4alkil, C1-4alkoksi, halogenom supstituiran C1-4alkil, halogenom supstituiran C1-4alkoksi, hidroksi skupinom supstituiran C1-4alkil, hidroksi, karboksi, cijano, nitro, amino, C1-4alkilamino i di(C1-4alkil)amino;
wherein the cycloalkyl, aryl, heteroaryl or heterocycloalkyl, whether alone or as part of a substituent group is optionally substituted with one to two substituents independently selected from the group consisting of halogen, hydroxy, oxo, carboxy, C1-4alkyl, C1-4alkoxy, C1-4alkoxy-carbonyl, nitro, cyano, amino, C1-4alkylamino and di(C1-4alkyl)amino; 
pri čemu je cikloalkil, aril, heteroaril ili heterocikloalkil, bilo da je samostalan ili dio supstituentske skupine, opcionalno supstituiran sa jednim do dva supstituenta koji se neovisno odabiru iz skupine koju sačinjavaju halogen, hidroksi, okso, karboksi, C1-4alkil, C1-4alkoksi, C1-4alkoksi-karbonil, nitro, cijano, amino, C1-4alkilamino i di(C1-4alkil)amino;
a is an integer from 0 to 1; 
je a prirodni broj od 0 do 1;
provided that the halogens on the halogen substituted C1-4alkyl or the halogen substituted C1-4alkoxy are selected from the group consisting of chloro and fluoro; 
uz uvjet da su halogeni elementi na halogenom supstituiranim C1-4alkilnim ili halogenom supstituiranim C1-4alkoksi skupinama odabiru iz skupine koju sačinjavaju kloro i fluoro;
wherein the phenyl or heteroaryl is optionally substituted with a substituent selected from the group consisting of fluoro substituted C1-4alkyl; 
pri čemu je fenil ili heteroaril opcionalno supstituiran sa supstituentom kojeg se odabire iz skupine koju sačinjava fluorom supstituirani C1-4alkil;
is selected from the group consisting of n-propyl, 4-hydroxy-n-butyl and 5-hydroxy-n-perityl; 
se R6 odabire iz skupine koju sačinjavaju n-propil, 4-hidroksi-n-butil i 5-hidroksi-n-peritil;
d is an integer from 0 to 1; 
je d prirodni broj od 0 do 1;
is selected from the group consisting of n-propyl, 4-hydroxy-n-butyl and 5-hydroxy-n-pentyl; 
se R6 odabire iz skupine koju sačinjavaju n-propil, 4-hidroksi-n-butil i 5-hidroksi-n-pentil;
is selected from the group consisting of n-propyl and 4-hydroxy-n-butyl; 
se R6 odabire iz skupine koju sačinjavaju n-propil i 4-hidroksi-n-butil;
is selected from the group consisting of -O- and -S-; is selected from the group consisting of -phenyl- and -phenyl-3-CH2-; L3 is selected from the group consisting of -NH-, -NH-C(O)- and -NH-SO2-; wherein the L3 is bound to the R7 phenyl at the 3-position; 
se L2 odabire iz skupine koju sačinjavaju -O- i -S-; se R7 odabire iz skupine koju sačinjavaju fenil i -fenil-3-CH2-; se L3 odabire iz skupine koju sačinjavaju -NH-, -NH-C(O)-, i -NH-SO2-, pri čemu je L3 vezan na R7 fenil na poziciji 3-;
A compound as in Claim 12, wherein the disorder mediated by β-secretase is selected from the group consisting of Alzheimer's disease (AD), mild cognitive impairment, senility, dementia, dementia with Lewy bodies, Down's syndrome, dementia associated with Parkinson's disease and dementia associated with beta-amyloid. 
Spoj prema Zahtjevu 12, naznačen time da se poremećaj posredovan β-sekretazom odabire iz skupine koja se sastoji od Alzheimerove bolesti (AD), blagog kognitivnog poremećaja, senilnosti, demencije, demencije sa Lewyjevim tjelešcima, Downovog sindroma, demencije povezane sa Parkinsonovom bolesti i demencije povezane sa beta-amiloidom.
wherein RQ is selected from the group consisting of hydrogen and C1-4alkyl; 
pri čemu se RQ odabire iz skupine koju sačinjavaju vodik i C1-4alkil;
Container (1) for storing and unloading bulk material comprising a vessel (2) presenting a closed extremity (3) and an opened extremity (4), characterized in that it comprises: 
Spremnik (1) za skladištenje i istovar rasutog materijala koji sadrži posudu (2) sa zatvorenim (3) i otvorenim krajem (4), naznačen time što sadrži:
Container according to Claim 1 wherein the vessel (2) is a cylinder. 
Spremnik u skladu s patentnim zahtjevom 1, naznačen time što posuda (2) je cilindar.
Container according to Claim 1 or 2 wherein the vessel (2) is made of at least a material chosen between: plastic, cardboard paper, aluminium or a mixture and/or laminate of the materials. 
Spremnik u skladu s patentnim zahtjevom 1 ili 2, naznačen time što posuda (2) je načinjena od, u najmanju ruku, materijala kojeg se bira između: plastike, kartona, aluminija ili smjese i/ili laminata materijala.
Container according to claim 9 wherein the tear lines are straight lines intersecting at the centre of the cover. 
Spremnik u skladu s patentnim zahtjevom 9, naznačen time što linije kidanja su ravne linije koje se sreću na sredini pokrova.
Method according to 18 where the volume of the tank is at least equal to the volume of the container and in a following step the container is disposed. 
Postupak u skladu s 18, naznačen time što volumen rezervoara je u najmanju ruku jednak volumenu spremnika, a u sljedećem koraku spremnik se baca u smeće.
Method according to Claim 18 where the volume of the tank is inferior to the volume of the container and in a following step the container is used as an expansion tank. 
Postupak u skladu s patentnim zahtjevom 18, naznačen time što volumen rezervoara je manji od volumena spremnika, a u sljedećem koraku spremnik se upotrebljava kao ekspanzijski rezervoar.
Use according to Claim 21 or 22 where the tank is a non disposable coffee powder jar. 
Upotreba u skladu s patentnim zahtjevom 21 ili 22, naznačena time što rezervoar je nebaciva posuda za kavu u prahu.
A structure according to claim 2, characterized in that the panels of electrically welded netting comprise at least double horizontal wires (42) and single vertical wires (44). 
bočne stijenke sadrže panele (40) od električki zavarene mreže sastavljene od dvostrukih horizontalnih žica (42) i jednostrukih vertikalnih žica (44).
A structure according to claim 2, characterized in that the support frames (20) comprise two lateral uprights (24) including a main structure (46) and a coupling plate (48) . 
Konstrukcija u skladu s patentnim zahtjevom 2, naznačena time, da potporni okviri (20) sadrže dva bočna stupića (24) uključujući glavnu konstrukciju (46) i spojnu ploču (48).
A structure according to claim 2, characterized in that the panels of electrically welded netting are secured between the main structure (46) and the coupling plate (48) of the lateral upright (24) of the support frame (20). 
Konstrukcija u skladu s patentnim zahtjevom 2, naznačena time, da su paneli od električki zavarenih mreža pričvršćeni između glavne konstrukcije (46) i spojne ploče (48) bočnog stupića (24) potpornog okvira (20).
A structure according to claim 1, characterized in that it also comprises means (60, 62) for anchoring the structure to the ground, which means are connected to the frame means (20). 
Konstrukcija u skladu s patentnim zahtjevom 1, naznačena time, da ona također sadrži sredstva (60, 62) za sidrenje konstrukcije u tlo, koja su sredstva povezana sa sredstvima okvira (20).
A compound according to Claim 1 wherein D is a steroid of the substructure IV: wherein Ra, Rb, are chosen independently of each other from the group conisting of hydrogen and halogen; 
Spoj u skladu s patentnim zahtjevom 1, gdje D je steroid podstrukture IV: [image], gdje Ra i Rb se, međusobno neovisno, bira iz skupine koju čine vodik i halogen;
Rf is chosen from the group consisting of hydrogen, hydroxyl group, halogen or forms (C=O) a carbonyl group with the carbon atom to which it is linked; 
Rf se bira iz skupine koju čine vodik, hidroksilna skupina, halogen, ili tvori karbonilnu skupinu s atomom ugljika na kojeg je vezan;
A compound according to claim 2 wherein R1, R2, R3, R4 and R5 are each independently chosen from the group consisting of hydrogen and C1-C4 alkyl. 
Spoj u skladu s patentnim zahtjevom 2, gdje R1, R2, R3, R4 i R5 se svakog neovisno bira iz skupine koju čine vodik i C1-C4alkil.
The compound according to claim 2 wherein R1, R2, R3, R4 and R5 are chosen independently from the group consisting of hydrogen and methyl. 
Spoj u skladu s patentnim zahtjevom 2, gdje R1, R2, R3, R4 i R5 se neovisno bira iz skupine koju čine vodik i metil.
The compound according to claim 2 wherein X1 is CH2 and X2 is NH. 
Spoj u skladu s patentnim zahtjevom 2, gdje X1 je CH2, a X2 je NH.
The method according to claim 33, wherein inflammatory conditions and immune disorders are selected from the group consisting of asthma, adult respiratory distress syndrome, chronic obstructive pulmonary disease, inflammatory bowel conditions, Crohn's disease, bronchitis, and cystic fibrosis. 
Upotreba spoja u skladu s patentnim zahtjevom 35, gdje upalna stanja i imunosne poremećaje se bira iz skupine koju čine astma, sindrom dišnog distresa kod odraslih, kronična opstruktivna plućna bolest, upalna stanja crijeva, Crohnova bolest, bronhitis, te cistična fibroza.
A method according to claim 33, wherein said inflammatory conditions and immune disorders are selected from the group consisting of asthma, adult respiratory distress syndrome, bronchitis, cystic fibrosis, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis, uveitis, conjunctivitis, inflammatory bowel conditions, Crohn's disease, ulcerative colitis, distal proctitis, psoriasis, eczema, dermatitis, coronary infarct damage, chronic inflammation, endotoxin shock, and smooth muscle proliferation disorders. 
Upotreba spoja u skladu s patentnim zahtjevom 35, gdje upalna stanja i imunosne poremećaje se bira iz skupine koju čine astma, sindrom dišnog distresa kod odraslih, bronhitis, cistična fibroza, reumatoidni artritis, reumatoidni spondilitis, osteoartritis, gihtični artritis, uveitis, konjunktivitis, upalna stanja crijeva, Crohnova bolest, ulcerozni kolitis, distalni proktitis, psorijaza, egzem, dermatitis, infarktno oštećenje koronarnih žila, kronična upala, endotoksinski šok, te poremećaji proliferacije glatkih mišića.
or a pharmaceutically acceptable salt, hydrate, solvate or complex thereof. 
ili njegova farmaceutski prihvatljiva soll, hidrat, otopina ili kompleks.
or a pharmaceutically acceptable salt, hydrate, solvate or complex thereof. 
ili njegova farmaceutski prihvatljiva sol, hidrat, otopina ili kompleks.